伐昔洛韦抑制疗法和间歇疗法预防生殖器疱疹复发作用比较

目的　比较伐昔洛韦每日抑制疗法和间歇疗法对预防生殖器疱疹复发的作用。方法　 65例复发性生殖器疱疹患者按不同复发频度分层后以半随机方式分配至间歇疗法组 (A组 )和每日抑制疗法组 (B组 )。A组 3 4例 ,当疱疹复发时口服伐昔洛韦 3 0 0mg ,2次 /d ,连服 6天 ;B组 3 1例 ,口服伐昔洛韦 3 0 0mg ,1次 /d ,连服 4个月。治疗后观察随访 6个月。结果　在 4个月治疗期间以及其后 6个月随访期间 ,B组每半年平均复发次数均显著低于A组 (P均 <0 .0 0 1)。结论　伐昔洛韦每日抑制疗法对预防和延迟生殖器疱疹复发具有显著作用 ,疗效明显优于间歇疗法。     

伐昔洛韦联合胸腺肽肠溶片间歇疗法预防复发性生殖器疱疹疗效观察

目的探讨治疗复发性生殖器疱疹的最佳方法。方法将入选的70例复发性生殖器疱疹患者按就诊顺序随机分成2组,对照组35例,口服伐昔洛韦0.3g,2次/d,连服6d;治疗组35例,口服伐昔洛韦0.3g,2次/d,每月连服6d,胸腺肽肠溶片10mg,3次/d,每月连服14d。两组患者的疗程均为4个月,治疗结束后随访6个月。结果在4个月治疗期间,治疗组复发率(14.72%)明显低于对照组(80.65%);在6个月随访期间,治疗组复发率(52.94%)也明显低于对照组(90.32%),差异均有统计学意义(P均<0.05)。结论伐昔洛韦联合胸腺肽肠溶片间歇疗法治疗复发性生殖器疱疹可有效控制疱疹复发,疗效较好,且治疗方法简单,患者的依从性较好。     

万乃洛韦 干扰素和胸腺肽治疗复发性生殖器疱疹的对比观察

目的　对比观察大剂量、长疗程的万乃洛韦、干扰素和胸腺肽分别治疗复发性生殖器疱疹 (RGH)的疗效和费用。方法　分别采用盐酸万乃洛韦 0 .3g口服 ,2次 /d ;α 2b干扰素 3 0 0万u肌注 ,隔日 1次 ;胸腺肽 50mg肌注 ,隔日1次 ,疗程均为 3个月。结果　 3组治愈率分别为 80 .0 %、75.0 %、76.5% ,各组疗前、疗后年人均复发次数比较差异均有显著性 (P均 <0 .0 1) ,但 3组治愈率比较差异均无显著性 (P均 >0 .0 5)。结论　大剂量、长疗程的万乃洛韦、干扰素和胸腺肽分别治疗RGH均有显著疗效 ,但以胸腺肽疗法不良反应少、费用低 ,值得临床推荐使用     

三种方法预防复发性生殖器疱疹疗效观察

目的探讨治疗复发性生殖器疱疹的有效方法。方法 A组42例,伐昔洛韦0.3g,1次/d;B组41例,阿昔洛韦0.4g,2次/d;C组37例,阿昔洛韦0.4g,转移因子6mg,2次/d,疗程均为6个月。结果各组复发率分别为23.80%,29.30%,18.90%,各组间差异无统计学意义。结论采用6个月抑制疗法治疗生殖器疱疹,可有效控制复发。     

盐酸万乃洛韦治疗带状疱疹疗效观察

目的:观察用盐酸万乃洛韦治疗带状疱疹的疗效和安全性,并与阿昔洛韦比较。方法:应用盐酸万乃洛韦每次300mg,每日2次,连服9天;阿昔洛韦每次200mg,每日5次,连服9天。结果:盐酸万乃洛韦在起效时间、结痴时间及痊愈时间上均较阿昔洛韦明显缩短,两者间有显著性差异(P<0.05)。结论:盐酸万乃洛韦治疗带状疱疹的疗效明显优于阿昔洛韦,且无明显毒副作用。     

多种药物治疗生殖器疱疹56例

我院从 2 0 0 0年 4～ 11月先后对 5 6例男性生殖器疱疹进行综合治疗 ,取得了较好的效果 ,现介绍如下 :1　临床资料　本组中年龄在 2 0～ 3 0岁的 4 1例 ,3 1～ 67岁的15例。初发者 2 6例 ,复发 3 0例 (复发 2次以上 )。本组中含有合并症者 3 2例 ,主要有淋病、非淋菌尿道炎、尖锐湿疣、前列腺炎等。2　治疗方法2 1　初发型　阿昔洛韦片 2 0 0ｍｇ 5次 /日× 15天 ;干扰素10 0万Ｕ 局封 1次 /周× 2 ,第三周起隔周 1次× 6;红外或紫外线照射 ;外搽阿昔洛韦膏等。2 2　复发型　盐酸万乃洛韦 0 61次 /日× 3 0天 ;更昔洛韦0 5ｉｖｇｔｔ×…     

三种方案治疗复发性生殖器疱疹疗效的比较

目的:比较三种治疗方案减少生殖器疱疹复发的临床效果。方法:107例频繁复发性生殖器疱疹患者(≥3次/半年)随机分成3组,Ⅰ组单纯口服万乃洛韦3个月,Ⅱ组口服万乃洛韦加肌注α-2b干扰素3个月,Ⅲ组口服万乃洛韦加局部外用5%咪喹莫特乳膏3个月。结果:三种方案治疗后半年复发频率均明显低于治疗前半年复发频率(P<0.01),且Ⅱ、Ⅲ组减少复发效果优于I组(P<0.01)。Ⅱ组与Ⅲ组疗效之间无显著性差异(P>0.05),Ⅲ组用药方便,但部分患者局部出现刺激反应。结论:三种治疗方案对减少频发性生殖器疱疹复发均具有显著作用,且Ⅱ、Ⅲ组疗效明显优于I组。     

伐昔洛昔联合甘露聚糖肽治疗复发性生殖器疱疹疗效观察

目的观察伐昔洛韦胶囊联合甘露聚糖肽针剂治疗复发性生殖器疱疹的疗效。方法治疗组45例口服伐昔洛韦胶囊0.3g/次,2次/d;甘露聚糖肽针5mg加利多卡因0.5mL局部皮下注射,3日1次,共10次。对照组40例予口服伐昔洛韦胶囊0.3g/次,2次/d。疗程均为1个月。治疗结束,随访1年。结果治疗组复发率22.2%,低于对照组复发率55.0%,无明显的不良反应。结论伐昔洛韦胶囊联合甘露聚糖肽针治疗生殖器疱疹疗效满意。     

伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹的临床效果及预后效果观察

目的:观察伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹的临床效果及预后效果。方法:从2012年8月至2014年8月我院收治的频发性生殖器疱疹中选取108例作为研究对象,按随机分组法分为A组和B组,各54例。A组采用持续抑制疗法,B组采用间歇疗法。分别于用药期间观察两组复发情况及不良反应。结果:A组在治疗期间与治疗后随访期间的复发率20.37%、48.15%,均低于B组的87.04%、92.59%;两组治疗后随访1年的复发次数均明显减少,且A组复发次数为(0.9±0.7)次,低于B组的(2.4±1.1)次。上述差异均有统计学意义(P0.05)。两组的不良反应发生率比较,差异无统计学意义(P0.05)。结论:伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹临床疗效显著,预后良好,值得临床推荐。     

卡介菌多糖核酸联合常规药物治疗非淋菌性尿道炎和生殖器疱疹的疗效观察

目的　观察卡介菌多糖核酸 (BCG PSN)联合常规药物治疗非淋菌性尿道炎和生殖器疱疹的疗效。方法　非淋菌性尿道炎联合组 3 0例采用BCG PSN注射联合阿奇霉素口服治疗 ,对照组 2 8例单用阿奇霉素口服治疗 ;生殖器疱疹联合组 2 2例采用BCG PSN注射联合万乃洛韦口服治疗 ,对照组 2 0例单用万乃洛韦口服治疗。结果　非淋菌性尿道炎联合组的痊愈率 (93 .3 3 % )显著高于其对照组 (67.86% ) (P <0 .0 5 ) ;生殖器疱疹联合组的复发率 (3 1.82 % )显著低于其对照组 (65 .0 0 % ) (P <0 .0 5 )。结论　BCG PSN联合常规药物治疗非淋菌性尿道炎的疗效好 ;治疗生殖器疱疹的复发率低。     

Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection

OBJECTIVE: To investigate whether suppressive antiviral therapy improves health related quality of life in patients with recurrent genital herpes. METHODS: Health related quality of life was measured using the disease specific recurrent genital herpes quality of life questionnaire (RGHQoL) as part of a randomized, double blind, 52 week, placebo controlled, dose ranging study of once and twice daily valaciclovir or aciclovir for the suppression of recurrent genital herpes in patients with six or more recurrences per year. RESULTS: Of 1479 participants, 1349 patients completed the baseline questionnaire. There were no significant baseline differences in RGHQoL score between any of the treatment groups. After 3 months there were significantly greater improvements in mean RGHQoL scores for all active treatment groups compared with placebo (p < 0.05). Mean RGHQoL score improvements from baseline remained significantly higher in the active treatment groups than in the placebo group after 6 and 12 months, indicating that the improved health related quality of life in patients receiving suppressive antiviral therapy was sustained over a prolonged period of time. CONCLUSION: Suppressive antiviral therapy is an effective strategy for improving the quality of life of patients with recurrent genital herpes. These improvements in quality of life are sustained over time, thus enhancing the clinical benefit in the long term management of this condition.     

Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.

OBJECTIVE: To determine the efficacy and safety of once daily valaciclovir for the suppression of recurrent genital herpes simplex virus (HSV) infection in immunocompetent patients. METHODS: 382 otherwise healthy patients with a history of frequently recurring genital HSV infection (eight recurrences per year) were randomly allocated to receive either oral valaciclovir (500 mg once daily) or placebo (3:1 ratio) for 16 weeks or until the first genital HSV recurrence, whichever occurred first. Patients were clinically assessed at regular intervals and also if they experienced a recurrence. Safety was evaluated through adverse experience reporting and monitoring of haematology and biochemistry variables. On completion of the double blind phase, patients were eligible for follow up to a maximum of 48 weeks' treatment with open label valaciclovir (500 mg once daily) for further safety monitoring. The results from the double blind phase of the study are reported here. RESULTS: A significant difference was detected between valaciclovir and placebo in the time to first recurrence of genital HSV infection. The hazard ratio [95% confidence interval] for valaciclovir v placebo was 0.155 [0.112, 0.214], p < 0.0001. Valaciclovir prevented or delayed 85% of the recurrences that would have occurred with placebo. After 16 weeks (day 112) with treatment, 69% of patients receiving valaciclovir were recurrence free compared with only 9.5% of patients assigned to placebo. The safety profiles of valaciclovir and placebo were comparable, with adverse experiences being infrequent and generally mild. CONCLUSION: This study has demonstrated that once daily valaciclovir (500 mg), is highly effective and well tolerated for the suppression of recurrent genital HSV infection. Once daily dosing with valaciclovir provides a more convenient dosing regimen than the more frequent aciclovir regimens.     

万乃洛韦结合膦甲酸钠注射液治疗复发性生殖器疱疹的临床效果观察

目的：研究万乃洛韦结合膦甲酸钠注射液治疗复发性生殖器疱疹的临床效果。方法：本组抽取我院于2011年4月至2013年4月收治的复发性生殖器疱疹患者58例,将患者随机均分为两组,观察组患者采用万乃洛韦结合膦甲酸钠注射液治疗,对照组患者采用阿昔洛韦治疗,观察两组患者的临床疗效以及病情复发情况。结果：观察组患者的治疗有效率和1年内病情未复发率分别为100％、62．07％;对照组组患者的治疗有效率和1年内病情未复发率分别为79．31％、24．14％,差异具有统计学意义（P〈0．05）。结论：复发性生殖器疱疹患者入院后,取万乃洛韦结合膦甲酸钠注射液治疗,能够降低疾病的复发率,值得推广使用。     

磷甲酸钠联合胸腺五肽治疗生殖器疱疹60例临床观察

目的评价磷甲酸钠联合胸腺五肽治疗生殖器疱疹的疗效和安全性。方法将入选的120例患者随机分为2组,治疗组60例,静滴磷甲酸钠250mg,并肌肉注射胸腺五肽1mg,均1次/d;对照组60例,口服伐昔洛韦300mg,2次/d,两组患者的疗程均为15d。结果两组治愈率均为100%,治疗组平均治愈时间(3.23±0.93)d明显短于对照组(4.35±1.04)d,差异有统计学意义(P<0.01)。治疗结束后6个月时治疗组复发率(28.33%)均明显低于对照组(46.67%),差异也有统计学意义(P<0.05)。治疗组仅有轻微的静脉刺痛、一过性低热和胃肠道反应,未影响疗程。结论磷甲酸钠联合胸腺五肽治疗生殖器疱疹能有效减少复发,安全性好。     

伐昔洛韦不同药物使用方案在女性复发性生殖疱疹中的疗效对比及安全性研究

目的:分析伐昔洛韦不同药物使用方案在女性复发性生殖疱疹中的疗效以及安全性,为提高女性复发性生殖疱疹的临床疗效及安全性提供科学依据。方法:选取2014年1月至2015年6月100例复发性生殖器疱疹女性患者,随机分为观察组与对照组,每组50例。所有患者均使用单药伐昔洛韦治疗,采用不同的用药方案。对照组连续用药7d,2次/d,300mg/次;观察组连续用药5d,2次/d,500mg/次。在治疗第1d(D1)、第3d(D3)、第5d(D5)以及第7d(D7),比较两组患者的临床疗效,观察两组治疗前、D1、D3的HSV检出率以及并发症发生率。结果:观察组与对照组在D1、D3、D5、D7的治疗有效率差异无统计学意义(P0.05);观察组与对照组在D1的HSV阳性率显著低于对照组(P0.05),两组在治疗前和D3的HSV阳性率无统计学意义(P0.05);两组治疗过程中的并发症发生率无统计学意义(P0.05)。结论:单次伐昔洛韦用药量增大能够提高复发性生殖器疱疹的临床疗效,能够缩短单纯疱疹病毒在皮损部位的存在时间,并且对用药安全性无任何影响。     

泛昔洛韦联合转移因子治疗复发性生殖器疱疹疗效观察

目的:探讨泛昔洛韦联合转移因子治疗复发性生殖器疱疹的疗效。方法:治疗组32例,口服泛昔洛韦片,每次250mg,3次/d,连用10d后改为每次250mg,2次/d;同时口服转移因子胶囊,每次6mg,3次/d;两种药物联用2个月后停药。对照组28例,仅口服泛昔洛韦片,用法及疗程同治疗组。结果:治疗组的治愈率及总有效率均较对照组明显提高,复发率显著下降。结论:联合使用泛昔洛韦和转移因子是治疗复发性生殖器疱疹的一种有效的方法。     

Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind,placebo-controlled studies

The oral antiviral valacyclovir, which is 3 to 5 times more bioavailable than its parent compound acyclovir, is a good candidate for effective therapy to suppress recurrent herpes labialis lesions. The efficacy of oral valacyclovir in the suppression of herpes labialis has not previously been reported. Two identical, randomized, double-blind, parallel-group studies were conducted to evaluate the efficacy of oral valacyclovir 500 mg (n=49) versus placebo (n=49) once daily for 16 weeks in the suppression of herpes labialis among patients with a history of 4 or more recurrent lesions in the previous year. Data from the studies were pooled for analysis. Twenty-eight patients (60%) in the valacyclovir group compared with only 18 patients (38%) in the placebo group were recurrence-free throughout the 4-month treatment period (P=.041). The mean time to first recurrence was significantly longer with valacyclovir (13.1 weeks) compared with placebo (9.6 weeks) (P=.016). The total number of recurrences in patients using valacyclovir was 24 compared with 41 in patients using placebo. The incidence of adverse events during the 4-month treatment period was slightly lower in the valacyclovir group (22 events, 33% of patients) compared with the placebo group (29 events, 39% of patients). The results of these small double-blind, placebo-controlled studies suggest that oral valacyclovir 500 mg once daily for 4 months is effective and well tolerated for the prevention of recurrent herpes labialis. More research with larger patient numbers is warranted to corroborate and extend these findings.     

Graded challenge in an aciclovir allergic patient

An immunocompetent woman presented with a hypersensitivity skin reaction following suppressive therapy with aciclovir for recurrent culture proved genital herpes simplex virus infection. She developed a similar reaction when treatment was changed to famciclovir. Without antiviral suppression her recurrences were frequent and distressing. Graded challenge was performed and she became tolerant to aciclovir. She successfully continued suppressive therapy for 1 year with no further hypersensitivity reactions or recurrences.     

吲哚美辛间歇口服预防生殖器疱疹复发的效果观察

目的 探讨吲哚美辛口服预防频繁复发的生殖器疱疹的效果。方法 选择无吲哚美辛口服禁忌证的频繁复发的生殖器疱疹患者(年复发频率6次以上)173例,分成4组(A,B,C,D),分别给予吲哚美辛联合阿昔洛韦口服、阿昔洛韦连续递减疗法、发作期阿昔洛韦治疗和单纯吲哚美辛间歇口服疗法。疗程1年,期间定期复诊,记录患者的药物反应、生殖器疱疹复发情况。结果 各组患者预防性治疗前的平均复发频率为9.6～10次/年,经过1年的连续性预防后,年均复发频率(中位数)分别为3次,3次,7次,4次;较1年前分别减少67%,70%,30%,62%。吲哚美辛的不良反应主要有轻度眼睑浮肿10%(3/30);阿昔洛韦主要有头疼、眩晕(10%)。结论 吲哚美辛间歇口服预防复发的生殖器疱疹有效,可以减少其复发频率62%～67%。